Abstract
Background Coronavirus disease 2019 (Covid-19) active cases continue to demand the development of safe and effective treatments. This is the first clinical trial to evaluate the safety and efficacy of oral thymic peptides.
Methods We conducted a nonrandomized phase 2 trial with a historic control group to evaluate the safety and efficacy of a daily 250-mg oral dose of thymic peptides in the treatment of hospitalized Covid-19 patients. Comparison based on standard care from registry data was performed after propensity score matching. The primary outcomes were survival, time to recovery and the number of participants with treatment-related adverse events or side effects by day 20.
Results A total of 44 patients were analyzed in this study, 22 in the thymic peptides group and 22 in the standard care group. There were no deaths in the intervention group, compared to 24% mortality in standard care by day 20 (log-rank P=0.02). The Kaplan-Meier analysis showed a significantly shorter time to recovery by day 20 in the thymic peptides group as compared with standard care (median, 6 days vs. 12 days; hazard ratio for recovery, 2.75 [95% confidence interval, 1.34 to 5.62]; log-rank P=0.002). No side effects or adverse events were reported.
Conclusion In patients hospitalized with Covid-19, the use of thymic peptides reported no side effects, adverse events, or deaths by day 20. When compared with registry data, a significantly shorter time to recovery and mortality reduction was measured. The Catholic University of Honduras Medical Research Group (GIMUNICAH) is working on a more extensive phase 3 trial.
Trial registration ClinicalTrials.gov NCT04771013. February 25, 2021.
Competing Interest Statement
Héctor M. Ramos Zaldívar, Karla G. Reyes-Perdomo, and Héctor Armando Alvarenga Andino designed the modified protocol for isolation of thymic peptides, which is patent pending. Héctor M. Ramos Zaldívar receives a grant for education from the Universidad Católica de Honduras. The rest of the authors declare no competing interests.
Clinical Trial
ClinicalTrials.gov Identifier: NCT04771013
Funding Statement
The research reported was funded by the Universidad Católica de Honduras.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Catholic University of Honduras IRB in Tegucigalpa gave approval for this work. The study was approved and registered by the national regulatory entity for clinical trials, the General Directorate for Regulatory Framework Surveillance of the Ministry of Health of Honduras (DGVMN) the eighth of February of 2021; enrollment began tenth of February of 2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Plan to Share Individual Participant Data (IPD): Yes Plan Description: All of the individual participant data collected during the trial, after deidentification. Supporting Materials: Study Protocol Supporting Materials: Statistical Analysis Plan (SAP) Supporting Materials: Informed Consent Form (ICF) Supporting Materials: Clinical Study Report (CSR) Supporting Materials: Analytic Code Time Frame: Beginning 3 months and ending 5 years following article publication. Email addresses hramos{at}unicah.edu; hmramos{at}uc.cl Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For individual participant data meta-analysis.
